These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

598 related items for PubMed ID: 24702274

  • 1. The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital.
    Marquínez-Alonso I, Escudero-Vilaplana V, Pernía S, Beléndez Bieler C, Fernández-Llamazares CM, Sanjurjo-Sáez M.
    J Clin Pharm Ther; 2014 Aug; 39(4):376-82. PubMed ID: 24702274
    [Abstract] [Full Text] [Related]

  • 2. Romiplostim in chronic immune thrombocytopenic purpura.
    Cersosimo RJ.
    Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
    [Abstract] [Full Text] [Related]

  • 3. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.
    Tarantino MD, Bussel JB, Blanchette VS, Despotovic J, Bennett C, Raj A, Williams B, Beam D, Morales J, Rose MJ, Carpenter N, Nie K, Eisen M.
    Lancet; 2016 Jul 02; 388(10039):45-54. PubMed ID: 27103127
    [Abstract] [Full Text] [Related]

  • 4. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy.
    Kuter DJ, Bussel JB, Newland A, Baker RI, Lyons RM, Wasser J, Viallard JF, Macik G, Rummel M, Nie K, Jun S.
    Br J Haematol; 2013 May 02; 161(3):411-23. PubMed ID: 23432528
    [Abstract] [Full Text] [Related]

  • 5. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).
    Bussel JB, Hsieh L, Buchanan GR, Stine K, Kalpatthi R, Gnarra DJ, Ho RH, Nie K, Eisen M.
    Pediatr Blood Cancer; 2015 Feb 02; 62(2):208-213. PubMed ID: 25345874
    [Abstract] [Full Text] [Related]

  • 6. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.
    Zeller MP, Heddle NM, Kelton JG, Hamilton K, Wang G, Sholapur N, Carruthers J, Hsia C, Blais N, Toltl L, Hamm C, Pearson MA, Arnold DM.
    Transfusion; 2016 Jan 02; 56(1):73-9. PubMed ID: 26400824
    [Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia.
    Cines DB, Wasser J, Rodeghiero F, Chong BH, Steurer M, Provan D, Lyons R, Garcia-Chavez J, Carpenter N, Wang X, Eisen M.
    Haematologica; 2017 Aug 02; 102(8):1342-1351. PubMed ID: 28411254
    [Abstract] [Full Text] [Related]

  • 8. Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura.
    Newland A.
    Eur J Haematol Suppl; 2009 Mar 02; (71):20-5. PubMed ID: 19200304
    [Abstract] [Full Text] [Related]

  • 9. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F, Barcellini W, Cantoni S, Carpenedo M, Caparrotti G, Carrai V, Di Renzo N, Santoro C, Di Nicola M, Veneri D, Simonetti F, Liberati AM, Ferla V, Paoloni F, Crea E, Volpetti S, Tuniz E, Fanin R.
    Am J Hematol; 2016 May 02; 91(5):E293-5. PubMed ID: 26910388
    [Abstract] [Full Text] [Related]

  • 10. Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia.
    Tarantino MD, Bussel JB, Blanchette VS, Beam D, Roy J, Despotovic J, Raj A, Carpenter N, Mehta B, Eisen M.
    Haematologica; 2019 Nov 02; 104(11):2283-2291. PubMed ID: 30846500
    [Abstract] [Full Text] [Related]

  • 11. A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice.
    Steurer M, Quittet P, Papadaki HA, Selleslag D, Viallard JF, Kaiafa G, Janssens A, Kozak T, Wadenvik H, Schoonen M, Belton L, Kreuzbauer G.
    Eur J Haematol; 2017 Feb 02; 98(2):112-120. PubMed ID: 27557853
    [Abstract] [Full Text] [Related]

  • 12. Real-world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: Results from the TRAIT study.
    Cooper N, Scully M, Percy C, Nicolson PLR, Lowe G, Bagot CN, Thachil J, Grech H, Nokes T, Hill QA, Bradbury C, Talks K, Dutt T, Evans G, Pavord S, Wexler S, Charania A, Collington SJ, Ervin A, Ramscar N, Provan D.
    Br J Haematol; 2024 Jun 02; 204(6):2442-2452. PubMed ID: 38429869
    [Abstract] [Full Text] [Related]

  • 13. Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia.
    Janssens A, Rodeghiero F, Anderson D, Chong BH, Boda Z, Pabinger I, Červinek L, Terrell DR, Wang X, Franklin J.
    Ann Hematol; 2016 Jun 02; 95(7):1077-87. PubMed ID: 27130310
    [Abstract] [Full Text] [Related]

  • 14. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T, Harada Y, Matsubara E, Suzuki T, Oyama T, Kasai M, Uchida T, Ogura M.
    J Clin Pharm Ther; 2012 Dec 02; 37(6):729-32. PubMed ID: 22583038
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness and safety of romiplostim among patients with newly diagnosed, persistent and chronic ITP in routine clinical practice in central and Eastern Europe: an analysis of the PLATON study.
    Skopec B, Sninska Z, Tzvetkov N, Ivanushkin V, Björklöf K, Hippenmeyer J, Mihaylov G.
    Hematology; 2021 Dec 02; 26(1):497-502. PubMed ID: 34238136
    [Abstract] [Full Text] [Related]

  • 16. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review.
    Zhang J, Liang Y, Ai Y, Xie J, Li Y, Zheng W.
    Expert Opin Pharmacother; 2017 Oct 02; 18(15):1543-1551. PubMed ID: 28845713
    [Abstract] [Full Text] [Related]

  • 17. Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.
    Jamali F, Lemery S, Ayalew K, Robottom S, Robie-Suh K, Rieves D, Pazdur R.
    Oncology (Williston Park); 2009 Jul 02; 23(8):704-9. PubMed ID: 19711585
    [Abstract] [Full Text] [Related]

  • 18. An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP).
    Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Iwato K, Okamoto S, Kurokawa M, Kirito K, Hashino S, Ninomiya H, Mori S, Yonemura Y, Usuki K, Wei H, Lizambri R.
    Int J Hematol; 2012 Jun 02; 95(6):652-9. PubMed ID: 22532046
    [Abstract] [Full Text] [Related]

  • 19. Use of romiplostim for primary immune thrombocytopenia in children.
    Escudero Vilaplana V, Aragonés JH, Fernández-Llamazares CM, Bieler CB, Rodríguez SM, Sáez MS.
    Pediatr Hematol Oncol; 2012 Mar 02; 29(2):197-205. PubMed ID: 22376020
    [Abstract] [Full Text] [Related]

  • 20. Romiplostim or standard of care in patients with immune thrombocytopenia.
    Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, Rodeghiero F, Chong BH, Wang X, Berger DP.
    N Engl J Med; 2010 Nov 11; 363(20):1889-99. PubMed ID: 21067381
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.